Saxagliptin, alogliptin, and cardiovascular outcomes.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

8 citing papers in PubMed.

1. Glucagon and heart in type 2 diabetes: new perspectives.Cardiovascular diabetology · 2016
   Review
2. Assessment of cardiovascular risk of new drugs for the treatment of diabetes mellitus: risk assessment vs. risk aversion.European heart journal. Cardiovascular pharmacotherapy · 2016
   Review
3. Diabetes Drugs and Cardiovascular Safety.Endocrinology and metabolism (Seoul, Korea) · 2016
   Review
4. Recent Advances in Dipeptidyl-Peptidase-4 Inhibition Therapy: Lessons from the Bench and Clinical Trials.Journal of diabetes research · 2015
   Review
5. Dipeptidyl Peptidase 4: A New Link between Diabetes Mellitus and Atherosclerosis?BioMed research international · 2015
   Review
6. Incretin-based therapies in prediabetes: Current evidence and future perspectives.World journal of diabetes · 2014
   Review
7. Dipeptidyl-peptidase-4 Inhibitors and Heart Failure: Class Effect, Substance-Specific Effect, or Chance Effect?Current treatment options in cardiovascular medicine · 2014
   Article
8. On the potential of acarbose to reduce cardiovascular disease.Cardiovascular diabetology · 2014
   Review

Corrections and comments

• Commented on by
  Saxagliptin, alogliptin, and cardiovascular outcomes.2014
• Commented on by
  Saxagliptin, alogliptin, and cardiovascular outcomes.2014
• Comment on
  Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus.2013
• Comment on
  Alogliptin after acute coronary syndrome in patients with type 2 diabetes.2013

Authors and funding

1 author.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as